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in the development of pancreatic ductal 
adenocarcinoma and is associated 
with attenuated disease progression
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Abstract 
Background: MicroRNA‑506 (miR‑506) has been reported to function in several tumors as a tumor suppressor gene 
or oncogene. However, the expression and role of miR‑506 in pancreatic ductal adenocarcinoma (PDAC) remains 
unclear. In this study, we aimed to evaluate the phenotype of miR‑506 in PDAC.
Methods: Using miRNA in situ hybridization, we examined the expression of miR‑506 in 113 PDACs and 87 paired 
normal pancreatic tissues. We evaluated miR‑506 expression in PDAC cells, normal pancreatic ducts, and acinus/
islands, and we analyzed the associations between miR‑506 expression and the clinicopathologic characteristics of 
PDAC patients.
Results: miR‑506 expression was higher in PDAC than in matched normal pancreatic ductal cells (P < 0.001). On the 
other hand, the combined group of well and moderately differentiated PDACs showed higher levels of miR‑506 than 
the poorly differentiated ones (P = 0.023). Moreover, miR‑506 expression was negatively associated with pathologic T 
category (P = 0.004) and lymph node metastasis (P = 0.033), suggesting that miR‑506 might inhibit the progression 
of PDAC.
Conclusions: Our results suggest that miR‑506 either plays a role as an oncogene in the tumorigenesis and a tumor 
suppressor in the progression or serves as a house‑keeping, tumor‑suppressing miRNA, whose expression can be 
activated by oncogenic signals in early development to hinder the progression of PDAC.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is a lethal 
malignancy, with a median patient survival of 6 months 
and a 5-year overall survival rate of 5% [1, 2]. The high 
rate of lethality from PDAC is primarily due to the 
advanced stage of disease at diagnosis, which precludes 
curative surgery and leads to a poor prognosis. Therefore, 
to improve patient survival, early diagnosis of PDAC is 
extremely important. Routine imaging methods, such as 
ultrasound, computed tomography, and magnetic reso-
nance imaging, are not sensitive enough in early detec-
tion of PDAC [3]. Although carbohydrate antigen 19-9 
(CA19-9) is considered the most useful biomarker in the 
early detection and prognostic assessment of PDAC, the 
sensitivity and specificity of circulating CA19-9 detec-
tion is still poor [4, 5]. At present, treatment options 
for patients with PDAC are limited. Gemcitabine-based 
chemotherapy remains the standard of care for patients 
with advanced PDAC, but intrinsic and acquired chem-
oresistance is common [6]. The epithelial growth factor 
receptor inhibitor erlotinib is the only targeted agent 
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currently used in the treatment of PDCA, but only a 
fraction of PDAC patients can benefit from it [7]. There-
fore, to develop more efficient diagnostic and thera-
peutic strategies for PDAC, we need to elucidate the 
molecular mechanisms underlying its development and 
progression.
MicroRNAs (miRNAs) are small non-coding RNAs 
that inhibit the expression of target genes by base pair-
ing to complementary sites in the 3′-untranslated region 
of target mRNAs, leading to translational repression or 
the degradation of the target mRNAs [8]. Recent stud-
ies have shown that miRNAs elicit oncogenic or tumor-
suppressive functions by directly targeting oncogenes or 
tumor suppressor genes, respectively [8–10]. Deregu-
lated miRNAs have been found to play pivotal roles in 
PDAC development and progression by affecting multi-
ple cellular processes, such as cell proliferation, apopto-
sis, survival, invasion, metastasis, and chemotherapeutic 
resistance of PDAC [11].
miR-506, located on Xq27.3, was identified as a mem-
ber of the miR-506-514 cluster (including miR-506, 
miR-507, miR-508, miR-509, miR-510, miR-513 and 
miR-514) and was preferentially expressed in the testes 
of primates [12]. miR-506 was shown to inhibit tumor 
progression by suppressing epithelial-to-mesenchy-
mal transition (EMT), cell migration and invasion, cell 
proliferation, and angiogenesis and by promoting cell 
senescence in ovarian, gastric, breast, colorectal, and 
liver cancers as well as glioma [13–26]. In contrast, the 
miR-506-514 cluster was shown to be an activator in 
initiating tumor transformation in malignant melanoma 
[27]. In pancreatic cancer cells, miR-506 was shown to 
inhibit cell proliferation by targeting Pim-3 proto-onco-
gene (PIM3), a member of the proto-oncogene PIM 
family [28]. Using real-time reverse transcription-poly-
merase chain reaction (qRT-PCR), Du et al. [28] exam-
ined the expression of miR-506 in 38 pancreatic cancers 
and matched adjacent normal tissues and found that 
71% (27/38) of cases exhibited down-regulated miR-506 
expression.
In this study, using miRNA in situ hybridization (ISH), 
we examined the expression of miR-506 in 113 PDAC 
and 87 matched normal pancreatic tissues. Consider-
ing the complicated constituents of pancreatic tissue, we 
believed that miRNA ISH that can be linked to morphol-
ogy is a more accurate option to demonstrate miR-506 
expression in specific cells. We evaluated the expression 
of miR-506 in PDAC cells, normal pancreatic ductal cells, 
acinar cells, and islands. In addition, we analyzed the 
relationship between miR-506 expression and clinico-
pathologic parameters to elucidate the role of miR-506 in 
the progression of PDAC.
Methods
Patients and tissue samples
We collected 200 formalin-fixed, paraffin-embedded 
pancreatic tissue samples (including 113 cases of tumor 
tissue and 87 cases of non-tumor tissue in the resection 
margin) from the Department of Pathology at Tian-
jin Medical University Cancer Institute and Hospital 
(Tianjin, China). All samples were from 113 patients 
with PDAC who underwent surgical operation between 
2007 and 2010, and none of the patients received any 
preoperative chemotherapy or radiotherapy. All speci-
mens and clinical data were collected after our study 
received approval from Institutional Review Board 
of Tianjin Medical University Cancer Institute and 
Hospital.
Tissue microarray construction
Tissue microarrays (TMAs) were constructed using a 
manual tissue microarray instrument (Beecher Instru-
ments, Sun Prairie, WI, USA) equipped with a 2.0-mm 
punch needle, as described previously [29]. Five TMA 
blocks were prepared for the 200 pancreatic tissue 
specimens. For each tissue sample, the typical area was 
selected based on the appearance of the original hema-
toxylin and eosin-stained slides. For the non-tumor tis-
sue in surgical resection, we chose the typical areas with 
normal pancreatic ducts. For the 87 patients with both 
PDAC and non-tumor tissues, the matched tumor and 
non-tumor tissues were placed in adjacent cores.
miRNA ISH
The 4-μm paraffin-embedded TMA sections were 
hybridized with the double-DIG-labelled miRCURY 
LNATM detection probe, hsa-miR-506 (38314-
15, Exiqon, Woburn, MA, USA) for 2  h at 55°C, as 
described previously [13, 14]. The digoxigenins were 
detected with a polyclonal anti-DIG antibody and an 
alkaline phosphatase-conjugated second antibody 
(Ventana, Tucson, AZ, USA), using Nitroblue tetra-
zolium-5-bromo-4-chloro-3-indolyl phosphate (NBT-
BCIP) as the substrate. The LNA U6 snRNA probe 
(Exiqon, Woburn, MA, USA) was used as a positive 
control for every TMA core, with blue staining in the 
nucleus. For miR-506, blue staining in the cytoplasm was 
defined as positive signals. Signals in tumor cells and pan-
creatic non-tumor tissue (pancreatic ducts, acinar cells, 
and islands) were quantified by two senior pathologists, 
using a previously described scoring system [13, 14] with 
some modifications. The signal intensity (0, no signal; 1, 
weak signal; 2, intermediate signal; and 3, strong signal) 
and the percentage of positive cells (0, 0%; 1, <25%; 2, 
25%–50%; and 3, >50%) were multiplied to obtain a score 
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(0, 1, 2, 3, 4, 6, or 9). Low and high miR-506 expression 
levels were defined as scores of <4 and ≥4, respectively.
Statistical analysis
Statistical analyses were performed using GraphPad 
Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA) 
and SPSS version 17.0 softwares (SPSS Inc., Chicago, IL, 
USA). Student’s t test and the Chi square test were used 
to compare miR-506 levels between different groups. All 
statistical tests were two-sided, and P values less than 
0.05 were considered statistically significant.
Results
Patient characteristics
Of the 113 patients with PDAC, 64 (56.6%) were men, 
and 49 (43.4%) were women. Patient age ranged from 31 
to 79 (median, 59) years. Fifty-two (46.0%) tumors were 
found in the head, 33 (29.2%) in the uncinate process, 
and 28 (24.8%) in the body and tail of the pancreas. Of 
the 113 PDAC patients, 79 (69.9%) underwent pancreati-
coduodenectomy, 30 (26.5%) distal pancreatectomy plus 
splenectomy, 2 (1.8%) pancreaticoduodenectomy plus 
portal vein replacement, 1 (0.9%) total pancreas resec-
tion, and 1 (0.9%) pylorus-preserving pancreaticoduo-
denectomy. The largest tumor diameter ranged from 1 to 
10 cm (4.2 ± 1.8 cm). Histopathologically, 10 (8.9%), 59 
(52.2%) and 44 (38.9%) PDACs were well, moderately, and 
poorly differentiated, respectively. Twenty-eight (24.8%) 
PDACs were limited to the pancreas (pathologic T cat-
egory (pT1 and pT2), whereas 85 (75.2%) PDACs invaded 
adjacent organs or spread to the abdominal cavity (pT3 
and pT4). Except the 15 patients for whom not enough 
information was available to evaluate the status of lymph 
node metastasis, lymph node metastasis was found in 21 
(18.6%) patients, and 77 (68.1%) patients had no lymph 
node metastasis.
miR‑506 expression was up‑regulated in PDAC compared 
with normal pancreatic ducts
Pancreatic lobules are composed of ducts, acinus and 
pancreatic islands. PDAC mainly originates from ductal 
cells. We specifically analyzed the miR-506 expression in 
PDAC and normal pancreatic ducts. Of the 113 PDACs 
analyzed on TMAs, three were not evaluable owing to 
tissue shedding, insufficient tumor cells, or invalid stain-
ing of the positive control (U6). Of the 87 pancreatic 
non-tumor tissues analyzed on TMAs, 75 and 69 were 
identified to have normal pancreatic ducts and acinus/
islands, respectively. The results of ISH showed that 
miR-506 expression was higher in PDAC than in the 
matched normal pancreatic ducts (Fig.  1a). Statistical 
analysis showed significant differences in all evaluable 
samples (P < 0.001, Fig. 1b). On the other hand, miR-506 
expression was significantly lower in PDAC than in nor-
mal pancreatic acinus/islands (P < 0.001; Fig. 1).
PDAC showed a higher miR‑506 expression compared 
with pancreatic intraepithelial neoplasia
Pancreatic intraepithelial neoplasia (PanIN) is a precur-
sor lesion of PDAC [30, 31]. PDAC is usually accompa-
nied by PanIN [32]. On TMA, we identified three PanINs 
together with PDAC or in non-tumor tissue. ISH results 
showed that, in all three patients, miR-506 expression 
was higher in PDAC than in PanIN, although the lim-
ited number of patients precluded statistical evaluation 
(Fig. 2).
Fig. 1 The expression of miR‑506 in pancreatic ductal adenocar‑
cinoma (PDAC) and matched normal pancreatic tissues. a Repre‑
sentative images of hematoxylin and eosin (HE) staining, U6 in situ 
hybridization (ISH) (positive control), and miR‑506 ISH. The circles 
indicate normal pancreatic ducts. b Statistical analysis showed that 
miR‑506 expression in PDACs is significantly higher than that in 
normal pancreatic ducts but lower than that in normal pancreatic 
acinus/islands
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Associations between miR‑506 expression 
and clinicopathologic parameters
We further analyzed the relationship between miR-
506 expression and clinicopathologic parameters in 
the 110 PDAC patients with available miR-506 ISH 
results. miR-506 expression was relatively stronger in 
well and moderately differentiated PDACs compared 
with poorly differentiated PDACs (Fig.  3). Statistical 
analysis revealed that the rate of high miR-506 expres-
sion in well and moderately differentiated PDACs was 
higher than that in poorly differentiated ones (P = 0.023; 
Table 1). Moreover, the rates of high miR-506 expression 
in the pT1-T2 and N0 groups were significantly higher 
than those in the pT3-T4 (P  =  0.004) and N1 groups 
(P = 0.033; Table 1), respectively. We found no associa-
tion between miR-506 expression and age, sex, or tumor 
site and size (Table 1).
Discussion
In this study, we demonstrated that miR-506 was up-
regulated in PDACs compared with normal pancreatic 
ducts. Du et  al. [28] examined miR-506 expression in 
38 PDAC patients with RT-PCR and showed that miR-
506 was significantly down-regulated in PDACs com-
pared with normal adjacent tissues. The reasons for the 
inconsistency may be owing to differences in the sample 
size and the testing method. One of the advantages of 
miRNA ISH is the combination of the morphology and 
the expression of miRNAs. The structure of the pancreas 
is complex and includes pancreatic ducts, acinus, and 
islands. Moreover, in normal pancreatic lobules, there 
are many more acinar cells than ductal cells. We think 
that, because most PDACs originate from ductal cells 
[33], comparing the expression of miR-506 in PDAC cells 
with that in normal pancreatic ductal cells to evaluate the 
role of miR-506 in PDAC is more accurate. Furthermore, 
one typical feature of PDAC is the obvious desmoplastic 
response. In addition, PDACs often have obscure bound-
aries, and the tumor cells usually invade into adjacent 
pancreatic acinus cells and pancreatic islands. Therefore, 
it is important to distinguish tumor cells from stromal 
cells and differentiate pancreatic ductal cells from the 
surrounding acinus and islands. The results of qRT-PCR 
are for the whole cells that were used for RNA extraction. 
If we want to evaluate the expression of specific cells, 
laser capture microdissection is suggested before RNA 
extraction and qRT-PCR. However, miRNA ISH has its 
disadvantages, such as it not being a quantitative method. 
To mitigate the disadvantage, we used a semi-quantita-
tive scoring system, as described in the Methods section, 
and performed the analysis in a relatively large patient 
population. Further studies are warranted to identify the 
expression of miR-506 in PDAC.
Fig. 2 The expression of miR‑506 in one PDAC and matched low‑
grade pancreatic intraepithelial neoplasia (PanIN). miR‑506 expression 
is obviously higher in PDAC than in the matched low‑grade PanIN
Fig. 3 The expression of miR‑506 in low‑grade (well and moderately 
differentiated) and high‑grade (poorly differentiated) PDACs. miR‑506 
expression is obviously higher in low‑grade PDACs than in high‑
grade ones
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Increasing evidence has demonstrated that PanIN is 
the most direct precursor lesion of PDAC [34]. Studies 
have shown that patients with benign pancreatic tumors 
whose surgery margin had high-grade PanIN were diag-
nosed with PDAC several months or several years after 
the surgery [35–37]. The molecular alteration is accu-
mulated during the progression from PanIN to PDAC 
[38]. Kirsten ras oncogene (KRAS) mutation was found 
in 36% of PanIN1A cases, 44% of PanIN1B cases, 87% 
of PanIN2/3 cases, and more than 90% of PDACs [35, 
39]; therefore, KRAS mutation was considered an early 
genetic alteration event of PDAC [40]. Cyclin-dependent 
kinase inhibitor 2A (CDKN2A) mutation can be found 
in PanIN2, and mutations of tumor protein p53 (TP53), 
breast cancer 2 (BRCA2), and SMAD family member 4 
(SMAD4) were found mainly in PanIN3 or PDAC, which 
were recognized as late events of PDAC initiation [41, 
42]. In our study, because of the limitation of TMA, we 
found only three low-grade PanINs in the non-tumor 
tissue or among tumor cells. However, in all three cases, 
miR-506 expression was higher in PDAC than in PanIN. 
Considering that miR-506 was up-regulated in PDAC 
compared with normal pancreatic ducts and low-grade 
PanIN, miR-506 may play a role as an oncogene in the 
late phase of PDAC initiation. Alternatively, the activa-
tion of miR-506 expression may be a result of feedback 
response of the tumor suppression system to oncogenic 
signaling. For house-keeping tumor suppressor genes 
such as TP53, such an oncogene-activated elevation is 
an important mechanism [43, 44]. Future studies will be 
needed to differentiate these two scenarios.
miR-506 was shown to inhibit EMT by targeting snail 
family transcriptional repressor 2 (SNAI2), vimentin 
(VIM), cadherin 2 (CDH2), CD151 molecule (CD151), 
ETS proto-oncogene 1 (ETS1), and enhancer of zeste 2 
polycomb repressive complex 2 subunit (EZH2) in ovar-
ian, breast, gastric, and colorectal cancers [13, 14, 17, 45, 
46]. In our study, miR-506 expression was significantly 
higher in well and moderately differentiated PDACs 
than in poorly differentiated ones. Compared with well 
and moderately differentiated tumors, the tumor glands 
in poorly differentiated PDACs are more irregular; they 
are even replaced with solid nests or trabeculae. Conse-
quently, the expression of E-cadherin and cell adhesion in 
cancer cells is lower in poorly differentiated PDACs than 
in well and moderately differentiated ones [47, 48], which 
was consistent with our finding of miR-506 down-regula-
tion in poorly differentiated PDACs. Further studies will 
be needed to evaluate cause and effect between miR-506 
expression and tumor differentiation.
Invasion and metastasis were involved in tumor pro-
gression. According to the TNM staging system of PDAC 
[49], the cancer cells at pT3 and pT4 stages (beyond the 
pancreas) are more invasive than those at pT1 and pT2 
stages (limited to the pancreas). Our data showed that 
miR-506 expression was lower in cancer cells at pT3 and 
pT4 stages than in those at pT1 and pT2 stages. Further-
more, we found lower levels of miR-506 in the PDACs 
with lymph node metastasis than in those without metas-
tasis. Therefore, miR-506 is likely to function as a tumor 
suppressor to attenuate progression of PDAC.
In summary, by using miRNA ISH in a large-scale 
study of PDAC and normal pancreatic tissues, we dem-
onstrated that miR-506 was up-regulated in PDAC com-
pared with normal pancreatic ducts. On the other hand, 
miR-506 expression was negatively associated with pT 
stage and lymph node metastasis, suggesting that miR-
506 might inhibit the de-differentiation and invasion of 
PDAC cells as a tumor suppressor. The bimodal pattern 
of miR-506 expression in different phases of PDAC sug-
gests that miR-506 either plays a role as an oncogene in 
the tumorigenesis and a tumor suppressor in the progres-
sion or serves as a house-keeping, tumor-suppressing 
miRNA, whose expression can be activated by oncogenic 
Table 1 The relationship between  miR-506 expression 
and clinicopathologic parameters in 110 PDACs
a No information about lymph node metastasis in 15 patients





 ≤59 57 41 (71.9) 16 (28.1) 2.194 0.139
 >59 53 31 (58.5) 22 (41.5)
Sex
 Men 63 45 (71.4) 18 (28.6) 2.327 0.127
 Women 47 27 (57.4) 20 (42.6)
Tumor site
 Head 51 35 (68.6) 16 (31.4) 1.551 0.461
 Uncinate 
process
32 22 (68.8) 10 (31.2)
 Body and tail 27 15 (55.6) 12 (44.4)
Tumor size (cm)
 ≤4 67 45 (67.2) 22 (32.8) 0.222 0.638
 >4 43 27 (62.8) 16 (37.2)
Histologic grade
 G1, G2 68 39 (57.4) 29 (42.6) 5.170 0.023
 G3 42 33 (78.6) 9 (21.4)
pT category
 T1, T2 28 12 (42.9) 16 (57.1) 8.482 0.004
 T3, T4 82 60 (73.2) 22 (26.8)
Lymph node metastasisa
 No 74 45 (60.8) 29 (39.2) 4.542 0.033
 Yes 21 18 (85.7) 3 (14.3)
Page 6 of 7Cheng et al. Chin J Cancer  (2016) 35:64 
signals in early development to hinder the progression of 
PDAC. Further studies are needed to gain deeper insights 
into the role and mechanism of miR-506 in PDAC.
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